Artemether-lumefantrine
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Malaria
Conditions
Malaria, Falciparum
Trial Timeline
Jun 1, 2005 → Nov 1, 2005
NCT ID
NCT00386750About Artemether-lumefantrine
Artemether-lumefantrine is a approved stage product being developed by Novartis for Malaria. The current trial status is terminated. This product is registered under clinical trial identifier NCT00386750. Target conditions include Malaria, Falciparum.
What happened to similar drugs?
10 of 18 similar drugs in Malaria were approved
Approved (10) Terminated (0) Active (8)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00386763 | Phase 3 | Completed |
| NCT00386750 | Approved | Terminated |
| NCT00709969 | Phase 3 | Completed |
Competing Products
20 competing products in Malaria